The DTX3L Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. This product features targeted disruption of the DTX3L gene, which encodes an E3 ubiquitin ligase critical for DNA damage repair and interferon signaling. The polyclonal format provides a heterogeneous knockout population, offering broad applicability for loss-of-function studies without the clonal selection inherent to monoclonal lines. Designed for researchers investigating ubiquitin-mediated processes and immune responses in lung cancer, these cells serve as a versatile tool for functional genomics and drug discovery.
The parental A-549 cell line is a widely used model of lung adenocarcinoma, originally established from a 58-year-old male patient. It harbors a KRAS G12S mutation, a hallmark of aggressive lung malignancies, and exhibits an epithelial morphology. A-549 cells are extensively characterized for studying oncogenic signaling, tumor progression, and therapeutic resistance. The presence of an active interferon-responsive machinery and functional DNA damage pathways makes this cell line particularly suitable for dissecting the roles of DTX3L within the context of human non-small cell lung cancer.
DTX3L is an E3 ubiquitin ligase that, upon interferon-gamma stimulation, is transcriptionally upregulated via STAT1 and STAT2. It complexes with PARP9 to ubiquitinate histone H2AX and other substrates at DNA damage sites, facilitating repair factor assembly and linking immune signaling to genomic stability. Upstream regulators include STAT1, STAT2, and IRF1, with pathway components such as IFNGR, JAK1, and ATM. Through its interactions with ubiquitin-conjugating enzymes, DTX3L modulates ubiquitin-mediated proteolysis and influences DNA repair kinetics. These activities position DTX3L at the nexus of innate immunity and the DNA damage response.
Disruption of DTX3L in A-549 cells creates a valuable model for exploring the interplay between oncogenic stress and interferon-regulated DNA repair. Given that KRAS-driven tumors often rely on robust DNA damage responses for survival under replicative stress, the knockout of DTX3L can reveal vulnerabilities in these pathways. This model is particularly relevant for studying how lung adenocarcinoma cells cope with genotoxic insults and inflammatory cues. Additionally, since DTX3L has been implicated in restricting viral replication, the knockout cells can be used to dissect host-pathogen interactions and assess the impact of interferon signaling deficits on cancer cell fitness. The A-549 background provides a clinically relevant epithelial context for investigating potential synthetic lethal relationships and resistance mechanisms.
These cells support diverse assays including Western blotting, RT-qPCR, immunofluorescence, flow cytometry, comet assay, and interferon reporter assays for DNA damage and signaling pathway analysis. Drug sensitivity screening can exploit DTX3L deficiency. Applications cover lung cancer research, DNA damage response, interferon signaling, and ubiquitin-proteasome pathway studies. The model allows investigation of the DTX3L-PARP9 complex and crosstalk between ubiquitination and immune signaling. For additional information, contact Ascent Research.
